Published: 17 May 2026 | 6.01 AM
Last Updated: 18 May 2026 | 6.30 AM
IPO Overview / Intro
Q-Line Biotec IPO is an SME book build issue comprising entirely a fresh issue of 62.53 lakh shares. The IPO opens for subscription on 21 May 2026 and closes on 25 May 2026. The company is proposed to be listed on the NSE SME platform on 29 May 2026.
Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing diagnostic reagents, consumables, IVD kits, pathology products and diagnostic healthcare equipment. The company serves hospitals, diagnostic laboratories and medical colleges across India through its manufacturing capabilities, distribution network and healthcare product portfolio.
👉 | IPO GMP | IPO Reviews | IPO Subscription | IPO Allotment
Key Highlights
| Particulars | Details |
|---|---|
| IPO Type | SME Book Build IPO |
| Issue Size | 62,53,200 Shares |
| Business | Diagnostic Reagents & IVD Products |
| Listing Exchange | NSE SME |
| Issue Nature | Fresh Issue Only |
| Price Band | To be Announced |
| Retail Application | Yet to be Announced |
| Listing Date | 29 May 2026 |
| Lead Manager | Hem Securities Ltd. |
| Registrar | Purva Sharegistry (India) Pvt. Ltd. |
Q-Line Biotec IPO GMP – Latest Update
| Particulars | Details |
|---|---|
| IPO GMP Today | Rs. NA |
| Kostak | NA |
| Subject to Sauda | NA |
| GMP Trend | Awaited |
Q-Line Biotec IPO Subscription Status – Live Update
| Investor Category | Subscription Status |
|---|---|
| QIB | Yet to Open |
| NII | Yet to Open |
| Retail | Yet to Open |
| Total | Yet to Open |
IPO Details at a Glance
| Particulars | Details |
|---|---|
| IPO Date | 21 May to 25 May 2026 |
| Listing Date | 29 May 2026 |
| Face Value | Rs. 10 per share |
| Price Band | To be Announced |
| Lot Size | To be Announced |
| Issue Type | Bookbuilding IPO |
| Sale Type | Fresh Issue Only |
| Listing At | NSE SME |
| Total Issue Size | 62,53,200 Shares |
| Fresh Issue | 62,53,200 Shares |
| Market Maker Portion | 3,13,200 Shares |
| Net Offer to Public | 59,40,000 Shares |
| Shareholding Pre Issue | 1,70,74,999 Shares |
| Shareholding Post Issue | 2,33,28,199 Shares |
IPO Timetable
| Event | Date |
|---|---|
| IPO Open | Thursday, 21 May 2026 |
| IPO Close | Monday, 25 May 2026 |
| Allotment Finalisation | Tuesday, 26 May 2026 |
| Refund Initiation | Wednesday, 27 May 2026 |
| Credit of Shares | Wednesday, 27 May 2026 |
| Listing Date | Friday, 29 May 2026 |
Reservation
| Investor Category | Shares Offered | % of Net Issue |
|---|---|---|
| QIB Shares Offered | 29,69,200 | 49.99% |
| Anchor Investor Portion | 17,81,200 | 28.48% |
| QIB (Ex Anchor) | 11,88,000 | 19.00% |
| NII Shares Offered | 8,91,600 | 15.01% |
| Retail Shares Offered | 20,79,200 | 35.00% |
| Market Maker Portion | 3,13,200 | 5.01% |
| Total Shares Offered | 62,53,200 | 100.00% |
Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | To be Announced | To be Announced | To be Announced |
| Retail (Max) | To be Announced | To be Announced | To be Announced |
| S-HNI (Min) | To be Announced | To be Announced | To be Announced |
| B-HNI (Min) | To be Announced | To be Announced | To be Announced |
Company Details
Q-Line Biotech Ltd., incorporated in 2010, is engaged in developing, manufacturing and marketing diagnostic reagents, consumables, pathology products and IVD healthcare solutions. The company also manufactures, imports and distributes diagnostic healthcare equipment for hospitals, laboratories and medical institutions.
The company operates across multiple healthcare diagnostic segments including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, Rapid Tests and POC Devices. It also manufactures and supplies pathology equipment and diagnostic devices catering to the growing healthcare diagnostics market in India.
Q-Line Biotech has built manufacturing capacity of approximately 1.4 million diagnostic kits annually along with manufacturing capability for Selectra Machines. The company focuses on research-driven manufacturing, reverse engineering, quality control and distribution expansion across India.
| Particulars | Details |
|---|---|
| Registered Office | 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh – 226012 |
| Phone | +91-522-2435570 |
| compliance@qlinebiotech.com | |
| Business Segment | Diagnostic Reagents & IVD Products |
| Core Products | Diagnostic Kits, Consumables, IVD Products, Pathology Equipment |
| Business Model | Manufacturing & Distribution |
| Employee Strength | 126 Employees + 223 Third Party Workers |
| Particulars | Details |
|---|---|
| Lead Manager | Hem Securities Ltd. |
| Registrar | Purva Sharegistry (India) Pvt. Ltd. |
Financials
| Particulars (Rs. Cr.) | Dec 2025 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Assets | 561.34 | 455.49 | 339.25 | 251.58 |
| Total Income | 236.50 | 322.58 | 206.45 | 184.81 |
| Profit After Tax | 38.69 | 28.13 | 34.44 | 32.10 |
| EBITDA | 64.23 | 71.32 | 37.63 | 32.98 |
| Net Worth | -0.04 | 189.95 | 161.81 | 127.37 |
| Reserves & Surplus | 2.13 | 188.37 | 160.24 | 125.79 |
| Total Borrowings | 243.85 | 164.95 | 96.91 | 73.65 |
Valuation
| Objects of the Issue | Estimated Amount (Rs. Cr.) |
|---|---|
| Working Capital Requirements | 93.50 |
| Repayment of Borrowings | 90.00 |
| General Corporate Purpose | Balance |
| Total | 183.50 |
| KPI | FY25 |
|---|---|
| ROE | 17.66% |
| ROCE | 23.74% |
| Debt/Equity | 0.87 |
| RoNW | 23.74% |
| PAT Margin | 8.97% |
| EBITDA Margin | 22.73% |
| Particulars | Pre IPO | Post IPO |
|---|---|---|
| Promoter Holding | 96.77% | NA |
| Market Cap | To be Announced | NA |
Chanakya View
Q-Line Biotec IPO operates in the fast-growing diagnostic healthcare and IVD products industry where demand visibility remains strong due to increasing healthcare awareness, rising pathology testing and expansion in hospital infrastructure.
The company has built a diversified product portfolio across reagents, molecular diagnostics, immunodiagnostics and diagnostic equipment segments. Its manufacturing capability, distribution reach and focus on research-driven healthcare products are key positives for long-term scalability.
Financially, the company has reported healthy revenue growth with improving EBITDA profile, though borrowings remain elevated. Investors should also consider risks associated with competitive healthcare markets, working capital intensity and regulatory compliance requirements in the diagnostics industry.
| Parameter | Chanakya View |
|---|---|
| Business Model | Diagnostic Healthcare & IVD |
| Financial Trend | Strong Growth |
| Margin Profile | Healthy |
| Valuation | Awaited |
| Risk Level | Moderate to High |
| Listing Appeal | Positive |
| Long-Term Appeal | Positive |
Chanakya View: Q-Line Biotec IPO appears to be an emerging healthcare diagnostics SME IPO benefiting from rising demand in the IVD and pathology industry. Strong manufacturing capabilities and diversified healthcare products support long-term scalability, though investors should monitor valuation and leverage position before aggressive exposure.
Frequently Asked Questions (FAQs)
What is Q-Line Biotec IPO GMP today?
Q-Line Biotec IPO GMP today is currently unavailable in the grey market. GMP activity is expected to emerge closer to the IPO listing date.
What is the Q-Line Biotec IPO price band?
The Q-Line Biotec IPO price band is yet to be officially announced by the company.
What is the Q-Line Biotec IPO lot size?
The minimum lot size for Q-Line Biotec IPO is yet to be announced.
When will Q-Line Biotec IPO list?
Q-Line Biotec IPO is scheduled to list on the NSE SME platform on 29 May 2026.